Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as doxorubicin use different ways to stop tumor
cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of
doxorubicin by making tumor cells more sensitive to the drug.
PURPOSE: Phase II trial to study the effectiveness of combining oblimersen with doxorubicin
in treating patients who have locally advanced, recurrent, or metastatic hepatocellular
carcinoma (liver cancer).
Phase:
Phase 2
Details
Lead Sponsor:
Princess Margaret Hospital, Canada University Health Network, Toronto